Austin, TX – According to filings with the U.S. Securities and Exchange Commission, Lung Therapeutics is raising $38,682,750.00 in new funding. Sources indicate as part of senior management President, Brian Windsor played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Lung Therapeutics

Lung Therapeutics pursues innovative treatments for underserved, life-threatening lung conditions. Our therapies for Idiopathic Pulmonary Fibrosis and Loculated Pleural Effusion bring hope to patients whose only treatment options may be invasive surgery or costly and ineffective drugs. We aim to create better pharmaceutical treatment options for IPF, LPE, and other underserved lung conditions.

To learn more about Lung Therapeutics, visit http://lungtx.com/

Contact:
Brian Windsor, President
737-802-1989
bwindsor@lungtx.com
https://www.linkedin.com/in/windsorbrian/

SOURCE: http://www.intelligence360.io
Copyright (c) 2019 SI360 Inc. All rights reserved